Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025

Jeroen van Kampen; Jolanda Voermans; Widia Soochit; Thibault Mesplède; Thijs van de Laar; Wil van der Reijden; David Burger; Noga Shalev; Ard van Sighem; Daniela Bezemer; Suzanne Jurriaans; Thomas van der Vaart; Hanna de Jong; Marc van der Valk

doi:10.2807/1560-7917.es.2026.31.8.2600108

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025

Jeroen van Kampen^*
, Jolanda Voermans
, Widia Soochit
, Thibault Mesplède
, Thijs van de Laar
, Wil van der Reijden
, David Burger
, Noga Shalev
, Ard van Sighem
, Daniela Bezemer
, Suzanne Jurriaans
, Thomas van der Vaart
, Hanna de Jong
, Marc van der Valk

^*Corresponding author for this work

Laboratory of blood-borne infections
Department of Medical Microbiology
Radboud University Medical Center
Stichting HIV Monitoring
Amsterdam UMC, Locatie UvA/AMC
Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

34 Downloads (Pure)

Abstract

Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025. Clinical history and laboratory findings indicate possible transmitted resistance. The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally.

Original language	English
Article number	2600108
Journal	Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Volume	31
Issue number	8
DOIs	https://doi.org/10.2807/1560-7917.es.2026.31.8.2600108
Publication status	Published - 26 Feb 2026

Bibliographical note

Publisher Copyright:
© 2026, European Centre for Disease Prevention and Control (ECDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.2807/1560-7917.es.2026.31.8.2600108Licence: CC BY

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025Final published version, 182 KBLicence: CC BY

Cite this

van Kampen, J., Voermans, J., Soochit, W., Mesplède, T., van de Laar, T., van der Reijden, W., Burger, D., Shalev, N., van Sighem, A., Bezemer, D., Jurriaans, S., van der Vaart, T., de Jong, H., & van der Valk, M. (2026). Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 31(8), Article 2600108. https://doi.org/10.2807/1560-7917.es.2026.31.8.2600108

@article{88cf46c770a04bfb94272b0af63c3aff,

title = "Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025",

abstract = "Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025. Clinical history and laboratory findings indicate possible transmitted resistance. The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally.",

author = "\{van Kampen\}, Jeroen and Jolanda Voermans and Widia Soochit and Thibault Mespl{\`e}de and \{van de Laar\}, Thijs and \{van der Reijden\}, Wil and David Burger and Noga Shalev and \{van Sighem\}, Ard and Daniela Bezemer and Suzanne Jurriaans and \{van der Vaart\}, Thomas and \{de Jong\}, Hanna and \{van der Valk\}, Marc",

year = "2026",

month = feb,

day = "26",

doi = "10.2807/1560-7917.es.2026.31.8.2600108",

language = "English",

volume = "31",

journal = "Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin",

issn = "1560-7917",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "8",

}

van Kampen, J , Voermans, J, Soochit, W, Mesplède, T, van de Laar, T, van der Reijden, W, Burger, D, Shalev, N, van Sighem, A, Bezemer, D, Jurriaans, S, van der Vaart, T, de Jong, H & van der Valk, M 2026, 'Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025', Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, vol. 31, no. 8, 2600108. https://doi.org/10.2807/1560-7917.es.2026.31.8.2600108

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. / van Kampen, Jeroen ; Voermans, Jolanda; Soochit, Widia et al.
In: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, Vol. 31, No. 8, 2600108, 26.02.2026.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025

AU - van Kampen, Jeroen

AU - Voermans, Jolanda

AU - Soochit, Widia

AU - Mesplède, Thibault

AU - van de Laar, Thijs

AU - van der Reijden, Wil

AU - Burger, David

AU - Shalev, Noga

AU - van Sighem, Ard

AU - Bezemer, Daniela

AU - Jurriaans, Suzanne

AU - van der Vaart, Thomas

AU - de Jong, Hanna

AU - van der Valk, Marc

PY - 2026/2/26

Y1 - 2026/2/26

N2 - Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025. Clinical history and laboratory findings indicate possible transmitted resistance. The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally.

AB - Transmitted integrase inhibitor resistance in newly diagnosed HIV remains rare. We report two cases with baseline resistance to all currently available integrase inhibitors in the Netherlands in 2025. Clinical history and laboratory findings indicate possible transmitted resistance. The cases are not phylogenetically linked, representing two independent introductions of integrase inhibitor resistant HIV into the Dutch population. These observations highlight the need for strengthened surveillance and prevention efforts in Europe and globally.

U2 - 10.2807/1560-7917.es.2026.31.8.2600108

DO - 10.2807/1560-7917.es.2026.31.8.2600108

M3 - Article

C2 - 41755723

SN - 1560-7917

VL - 31

JO - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

IS - 8

M1 - 2600108

ER -

van Kampen J , Voermans J, Soochit W, Mesplède T, van de Laar T, van der Reijden W et al. Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2026 Feb 26;31(8):2600108. doi: 10.2807/1560-7917.es.2026.31.8.2600108

Two cases of possible transmitted HIV drug resistance to all currently available integrase inhibitors, the Netherlands, 2025

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this